Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye
Medical hypothesis discovery and innovation in ophthalmology,
Vol. 2 No. 4 (2013),
1 December 2013
,
Page 113-120
Abstract
This article reviews the new clinically relevant data regarding the intraocular treatment of non-infectious uveitis. Triamcinolone acetonide is the most commonly used intravitreal corticosteroid for treatment of uveitis and uveitic macular oedema. The drug is available at low cost but it is associated with a high risk of raised intraocular pressure (IOP) and cataract and is not licensed for intraocular use. Dexamethasone implant (Ozurdex®) appears to have a better safety profile, and a slightly long-lasting effect than triamcinolone acetonide. Fluocinolone acetonide implant (Retisert®) implant allows the release of corticosteroids at a constant rate over a 3-year period, but it requires surgical placement and its use is associated with a very high risk of cataracts and raised intraocular pressure. Iluvien® is another fluocinolone acetonide implant that could represent a more convenient treatment option for such cases in the future as it can be inserted into the vitreous cavity through 25-gauge injector system in an outpatient setting. To circumvent the risks associated with corticosteroids use, non-corticosteroids related therapeutics including intravitreal methotrexate; anti-vascular endothelial growth factor treatments and intravitreal sirolimus have been recently developed.
References
Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004 Sep;88(9):1159-62. PMID: 15317708
In: European Medicines Agency. Public summary of opinion on orphan designation.Dexamethasone (intravitreal implant) for the treatment of non-infectious uveitis affecting the posterior segment of the eye. November 2010. Available from: www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/08/WC500095728.pdf
Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004 Dec;138(6):1046-8. PMID: 15629301
Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol. 2009;3:41-7. PMID: 19668543
Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomised and nonvitrectomised eyes. Retina. 2005 Jul-Aug;25(5):556-60. PMID: 16077349
Kok H, Lau C, Maycock N, McCluske P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916. e1-1916.e7.
van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006 Apr;14(2):73-85. PMID: 16597536
Angunawela RI, Heatley CJ, Williamson TH, Spalton DJ, Graham EM, Antcliffe RJ, Stanford MR. Intravitreal triamcinolone acetonide for refractory uveitic cystoid macular oedema: long term management and outcome. Acta Ophthalmol Scand. 2005 Oct;83(5):595-9. PMID: 16187999
Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004 Nov;138(5):740-3. PMID: 15531307
Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545-53. PMID: 21220619
Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina. 2006 Oct;Suppl:1-16. PMID: 17050954
Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA.Ocular pharmacokinetics of fluocinoloneacetonide after Retisertintravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther. 2004 Jun;20(3):269-75. PMID: 15279731
Jaffe GJ. Reimplantation of a fluocinoloneacetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol. 2008 Apr;145(4):667-675. PMID: 18226800
Yeh S, Cebulla CM, Witherspoon SR, Emerson GG, Emerson MV, Suhler EB, Albini TA, Flaxel CJ. Management of fluocinoloneimplant dissociation during implant exchange. Arch Ophthalmol. 2009 Sep;127(9):1218-21. PMID: 19752436
Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinoloneacetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008 Sep;126(9):1191-201. PMID: 18779477
Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; FluocinoloneAcetonide Uveitis Study Group. Fluocinoloneacetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006 Jun;113(6):1020-7. PMID: 16690128
Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinoloneacetonide implant to treat posterior uveitis. Ophthalmology. 2005 Jul;112(7):1192-8. PMID: 15921758
Patel CC, Mandava N, Oliver SC, Braverman R, Quiroz-Mercado H, Olson JL. Treatment of intractable posterior uveitis in pediatric patients with thefluocinoloneacetonideintravitreal implant (Retisert). Retina. 2012Mar;32(3):537-42. PMID: 21963487.
Hebson CB, Srivastava SK. A functional, nonfunctioning Retisert implant. Ocul Immunol Inflamm. 2011 Jun;19(3):210-1. PMID: 21595538
Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinoloneacetonide (Retisert) implant. Am J Ophthalmol. 2007 Feb;143(2):334-5. PMID: 17258523
Ramaiya KJ, Rao PK. Herpetic necrotizing retinitis following flucinoloneacetonideintravitreal implant. Ocul Immunol Inflamm. 2011 Feb;19(1):72-4. PMID: 21034309
Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010 Apr;149(4):550-561.e10. PMID: 20097325
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Randomized comparison of systemic anti-inflammatory therapy versus fluocinoloneacetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011 Oct;118(10):1916-26. PMID: 21840602
Kane FE, Burdan J, Cutino A, Green KE. Iluvein: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv. 2008 Sep;5(9):1039-46. PMID: 18754752
Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F; Famous Study Group. Sustained ocular delivery of fluocinoloneacetonide by an intravitreal insert. Ophthalmology. 2010 Jul;117(7):1393-9.e3. PMID: 20202684
Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001 Nov;132(5):794-6. PMID: 11704050
Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996 Jan 12;271(2):736-41. PMID: 8557680
van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol. 2006 Jul;142(1):192-4. PMID: 16815285
Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol. 2009 Aug;148(2):303-309.e2. PMID: 19427988
Lasave AF, Zeballos DG, El-Haig WM, DÃaz-Llopis M, Salom D, Arevalo JF. Short term results of a single intravitrealbevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (Kenacort) in the management of refractory non-infectious uveitic cystoid macular oedema. Ocul Immunol Inflamm. 2009 Nov-Dec;17(6):423-30. PMID: 20001264
Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitrealbevacizumab compared with intravitreal and posterior subtenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina. 2011 Jan;31(1):111-8. PMID: 20856170
Soheilian M, Rabbanikhah Z, Ramezani A, Kiavash V, Yaseri M, Peyman GA. Intravitrealbevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular oedema: a randomized pilot study. J Ocul Pharmacol Ther. 2010 Apr;26(2):199-206. PMID: 20307215
Cervantes-Castañeda RA, Giuliari GP, Gallagher MJ, Yilmaz T, MacDonell RE, Quinones K, Foster CS. Intravitrealbevacizumab in refractory uveitic macular oedema: one year follow up. Eur J Ophthalmol. 2009 Jul-Aug;19(4):622-9. PMID: 19551679
Adán A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitrealbevacizumab (Avastin) injection as primary treatment of inflammatory choroidalneovascularisation. Retina. 2007 Nov-Dec;27(9):1180-6. PMID: 18046222
Chan WM, Lai TY, Liu DT, Lam DS.Intravitrealbevacizumab (Avastin) for choroidalneovascularisation secondary to central serous retinopathy, secondary to punctuate inner choroidopathy, or of idiopathic origin. American Journal of Ophthalmology. 2007 June;143(6):977-83.e1.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA study group. Ranibizumab for neovascular age related macular degeneration. N Eng J Med. 2006Oct; 355:1419-31.
Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit. 2001 Oct;23(5):559-86. PMID: 11591905
Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998 Jul;31(5):335-40. PMID: 9721431
Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):454-60. PMID: 15671269
Nguyen QD, Ibrahim MA, Watters A, Bittencourt M, Yohannan J, Sepah YJ, Dunn JP, Naor J, Shams N, Shaikh O, Leder HA, Do DV. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013 Feb 11;3(1):32. PMID: 23514595
Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004 Oct;138(4):648-50. PMID: 15488796
Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N. Infliximab for recurrent, sight threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004 Mar 2;140(5):404-6. PMID: 14996689
Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet disease. Lancet. 2001 Jul 28;358(9278):295-6. PMID: 11498218
Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina. 2010 Jan;30(1):71-80. PMID: 19996827
Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well designed trial. Retina. 2010 Jan;30(1):1-5. PMID: 20061905
Tsilimbaris M, Diakonis VF, Naoumidi I, Charisis S, Kritikos I, Chatzithanasis G, Papadaki T, Plainis S. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1119-25. PMID: 19296122
Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitrealadalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010 Aug;117(8):1612-6. PMID: 20378179
Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992 Sep;99(9):1419-23. PMID: 1407973
Ali A, Rosenbaum JT. Use of methotrexate in patients with uveitis. Clinical and experimental rheumatology. 2010;28(5):S145-S150.
Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H. Intraocular methotrexate in ocular disease other than primary central nervous system lymphoma. Am J Ophthalmol. 2006 Nov;142(5):883-5. PMID: 17056381
Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular oedema. Ophthalmology. 2009 Apr;116(4):797-801. PMID: 19344827
- Abstract Viewed: 3184 times
- FULL TEXT PDF Downloaded: 3063 times
